It has been hypothesized that one of the benefits of bosentan relates to pulmonary vascular remodeling. The investigators believe that this study will help document the nature of beneficial changes that occur in patients with Pulmonary Arterial Hypertension (PAH) in response to bosentan therapy. In turn, demonstrating that changes in pulmonary vascular structure and function accompany clinical improvement.
Subjects will have Optical coherence tomography (OCT) and Intravascular Ultrasound (IVUS) imaging during the right heart catheterization that diagnoses them as having PAH. Subjects will start their bosentan and will be followed by monthly clinic visits for 4 months. At 4 months they will have repeat OCT and IVUS imaging.
Study Type
INTERVENTIONAL
Allocation
NA
Masking
NONE
All subjects will have OCT and IVUS imaging during their right heart catheterization.
All subjects will have OCT and IVUS imaging during their right heart catheterization.
Massachusetts General Hospital
Boston, Massachusetts, United States
Change in the measurement of Pulmonary arterial intimal + Medial thickening by OCT pre and post treatment with bosentan at 4 months
Time frame: Baseline and 4 months
Change in pulmonary arterial pulsatility by IVUS pre and post treatment with bosentan at 4 months
Time frame: Baseline and 4 months
Change in pulmonary arterial pressure/elastic strain index by IVUS pre and post treatment with bosentan at 4 months
Time frame: Baseline and 4 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.